Navigation Links
Avoiding a cartography catastrophe
Date:2/4/2013

KNOXVILLE, TN Since the mid-nineteenth century, maps have helped elucidate the deadly mysteries of diseases like cholera and yellow fever. Yet today's global mapping of infectious diseases is considerably unreliable and may do little to inform the control of potential outbreaks, according to a new systematic mapping review of all clinically important infectious diseases known to humans.

Of the 355 infectious diseases assessed in the review, 174 showed a strong rationale for mapping and less than 5 percent of those have been mapped reliably. Unreliable mapping makes it difficult to fully understand the geographic scope and threat of disease and therefore make informed policy recommendations for managing it, write the authors of the study, which appears as open access on Feb. 4 in the journal Philosophical Transactions of the Royal Society B.

An online, open-access database, which accompanies the study, provides a quantitative scheme for evaluating the quality of data available for each infectious disease as well as specific mapping recommendations for each disease. Among the recommendations for improving disease cartography are the use of new crowdsourcing techniques to gather data, such as analyzing the content and frequency of Twitter messages about disease. Twitter feeds during the 2009 H1N1 flu outbreak, for example, predicted outbreaks sooner than traditional disease surveillance methods.

"We have shown that novel solutions exist to enable us to use up-to-date data and technology to rapidly improve our geographic knowledge of a wide range of clinically important pathogens," said Katherine Battle, one of the study's co-authors from the University of Oxford.

Unique to the review is the inclusion of how the basic reproduction rate, which is the primary epidemiological number used to determine the degree which a disease can spread through a population, might vary among pathogens.

"There is a clear need for better estimates of the potential growth of infectious diseases that allow spatial variations to be taken into consideration, and this paper is a wonderful contribution to help us meet this need," said Louis Gross, the director of the National Institute for Mathematical and Biological Synthesis, which sponsored a workshop in 2011 that produced the paper.


'/>"/>

Contact: Catherine Crawley
ccrawley@nimbios.org
865-974-9350
National Institute for Mathematical and Biological Synthesis (NIMBioS)
Source:Eurekalert  

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Avoiding a cartography catastrophe
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 8.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/20/2017)... , March 20, 2017 At this year,s ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand ... is this year,s CeBIT partner country. At the largest German biometrics ... in use: fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics ... ...
Breaking Biology News(10 mins):
(Date:5/18/2017)... ... 2017 , ... Many complicated neurological disorders appear to have ... while men are at greater risk for Parkinson’s disease. Understanding some of the ... of a research program at Worcester Polytechnic Institute (WPI) funded by a new ...
(Date:5/16/2017)... , ... May 16, 2017 , ... ... and cancer diagnostics, has released its ClearID Lung Cancer blood test. Leveraging a ... cancer, this new test is designed to quickly and accurately identify tumor-related genetic ...
(Date:5/15/2017)... ... May 15, 2017 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it has signed an agreement ... support preclinical and clinical development of TA-46, a novel protein addressing achondroplasia, which ...
(Date:5/12/2017)... , May 12, 2017  Eli Lilly and Company ... galcanezumab, an investigational treatment for the prevention of ... in three Phase 3 studies (EVOLVE-1, EVOLVE-2 and ... of monthly migraine headache days compared to placebo ... robust results from these three studies bring us ...
Breaking Biology Technology: